Clinton Stewart, PharmD

Clinton F. Stewart, PharmD

Member, St. Jude Faculty

Departments

Pharmaceutical Sciences

Contact Information

Clinton Stewart, PharmD
Pharmaceutical Sciences
MS313, Room D1052B
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: clinton.stewart@stjude.org
Phone: (901) 595-3665
FAX: (901) 525-6869

Education

PharmD - University of Tennessee, Memphis, Tennessee


Research Interests

  • Clinical pharmacokinetics, pharmacodynamics, and pharmacogenetics of anticancer drugs in children
  • Role of ABC transporters in CNS penetration of camptothecin analogs
  • Multidrug resistance proteins (e.g., MRP4, BCRP) in camptothecin pharmacology and physiology
  • Novel methods to optimize drug exposure in children with cancer (pharmacokinetically guided dosing)
  • Use of preclinical models to enhance design of clinical trials of new agents in children with cancer
  • Role of pharmacokinetics in drug development in pediatric oncology
  • Use of clinical pharmacology to optimize therapy for children with primary CNS malignancies

Selected Publications

Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA, Stewart CF. Compartment-specific roles of ABC transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Research 2009 (in press).

Furman WL, Navid F, Daw NC, McCarville B, McGregor LM, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KC, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 2009 (in press).

Bai F, Fraga CH, Tagen M, Schaiquevich P, Hagedorn N, Stewart CF. Simultaneous determination of cyclophosphamide and carboxyphosphamide mustard in human plasma using online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chrom B 2009 (in press).

Broniscer A, Baker SJ, Stewart CF, Merchant TE, Laningham FH, Schaiquevich P, Kocak M, Morris EB, Endersby R, Ellison DW, Gajjar A. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clinical Cancer Research 15:701-7, 2009.

Narang VS, Fraga C, Kumar N, Shen J, Throm S, Stewart CF, Waters CM. Dexamethasone increases expression and activity of multi-drug resistance transporter at the rat blood-brain barrier. Am J Physiol – Cell Physiology 295:C440-50, 2008.

Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, Gronewold L, Stewart CF, Wallace D, Broniscer A, Hale GA, Kasow KA, Merchant TE, Morris B, Krasin M, Kun LE, Boyett JM, Gajjar A. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 26:3749-55, 2008.

Wagner LM, Villablanca JC, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JP, Maris JM, Hawkins RA, Daldrup-Link H, Jackson HA, Matthay KK. Phase I study of oral irinotecan and temozolomide in children with relapsed high-risk neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium study. J Clin Oncol 27:1290-1296, 2009.

Shen J, Fraga C, Calabrese C, McCarville M, Schaiquevich P, Stewart CF. A modified surgical procedure for microdialysis probe implantation in the lateral ventricle of a FVB mouse. J Pharmaceutical Sciences 97:5013-5023, 2008.

MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Young-Poussaint T, Boyett JM, Kun LE, and Kieran MW. Phase I Clinical Trial Of Cilengitide (EMD 121974) In Children With Refractory Brain Tumors: A Pediatric Brain Tumor Consortium Study (PBTC-012). J Clin Oncol 20:919-24, 2008.

Panetta JC, Schaiquevich P, Santana VM, Stewart CF. Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma. Clin Cancer Res 14:318-325,2008.

Gururangan S, Turner CD, Stewart CF, O’Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, and Kun LE. Phase I trial of VNP40101M (CLORETAZINE®) in children with recurrent brain tumors - A Pediatric Brain Tumor Consortium (PBTC) study. Clin Cancer Research 15:1124-30, 2008.

Spunt SL, Freeman BB III, Billups CA, McPherson V, Khan RB, Pratt CB, Stewart CF. A Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. J Clin Oncol 25: 2274-2280, 2007.

Metzger ML, Stewart CF, Freeman BB, Billups C, Hoffer FA, Wu J, Coppes MJ, Grant R, Chintagumpala M, Mullen E, Alvarado C, Daw NC, Dome JS. Topotecan is active against Wilms tumor: Results of a multi-institutional Phase II study. J Clin Oncol 20:3130-3136, 2007.

Stewart CF, Panetta JC, O’Shaughnessy MA, Throm SL, Fraga CH, Owens T, Liu T, Billups C, Rodriguez-Galindo C, Gajjar A, Furman WL, McGregor LM. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 25:2594-2600, 2007.

Schaiquevich P, Panetta JC, Iacono LC, Freeman BB III, Santana VM, Gajjar A, Stewart CF. Population pharmacokinetic analysis of topotecan in pediatric patients with cancer. Clin Cancer Res 13:6703-6711, 2007.

Motl S, Zhuang Z, Waters CM, Stewart CF. Pharmacokinetic considerations in the treatment of CNS tumors. Clin Pharmacokinetics 2006;45: 871-903.

Chintagumpala MM, Friedman HS, Stewart CF, Kepner J, Mclendon RE, Modrich PL, McCluggage C, Burger P, Holmes E, Thompson S, Rutka J, Michalski J, Woo S, Blaney SM, Kun L, Horowitz ME. A Phase II window trial of procarbazine and topotecan in children with high-grade glioma. J NeuroOncology 77: 193-198, 2006.

Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC, Iacono LC, Merchant TE, Stewart CF, Houghton PJ, Kun LE, Ledet D, and Gajjar A. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol 76:313-319, 2006.

Laurie NA, Gray JK, Brannon C, Balbi K, Zhang J, Leggas M, Relling M, Egorin M, Stewart C, Dyer MA. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res 11:7569-7578, 2005.

Bai F, Freeman BB, Fraga CH, Stewart CF. Determination of lapatinib (GW572016) in human plasma by liquid chromatography tandem mass spectrometry (LC ESI-MS/MS). J Chrom B 831:169-175, 2006.

Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, Stewart CF. In vivo inhibition of multiple ABC transporters by an oral tyrosine kinase inhibitor. Cancer Res 66:4802-4807, 2006.

Wilson MW, Fraga CH, Fuller CE, Rodriguez-Galindo C, Mancini J, Hagedorn N, Leggas ML, Stewart CF. Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Invest Ophthalmol Vis Sci 47:1269-1273, 2006.

Dickson PV, Hagedorn NL, Hamner JB, Fraga CH, Ng CYC, Stewart CF, Davidoff AM. Interferon-β mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model. J Pediatr Surg 42:160-165, 2006.

Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart Clinton F, Dauser R, Sanford Robert A, Fuller Christine, Lau Ching, Boyett James M, Wallace Dana, Gilbertson Richard J. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncology 7:813-820, 2006.

Zhuang Y, Fraga CH, Hubbard KE, Hagedorn N, Panetta JC, Waters CM, Stewart CF. Topotecan CNS Penetration is Altered by a Tyrosine Kinase Inhibitor. Cancer Research 66:11305-11313,2006.

Freeman BB, Iacono LC, Panetta JC, Gajjar A, Stewart CF. Using plasma plasma topotecan pharmacokinetics to estimate CSF topotecan in children with medulloblastoma. NeuroOncology 8:89-95, 2006.

Turner PK, Iacono LC, Panetta JC, Santana VM, Daw NC, Gajjar A, Stewart CF. Development and Validation of Limited Sampling Models for Topotecan Lactone Pharmacokinetic Studies in Children. Cancer Chemother Pharmacol 57:475-482, 2006.

Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ, Stewart CF. Improved Response in High-Risk Neuroblastoma with Protracted Topotecan Administration Using a Pharmacokinetically Guided Dosing Approach. J Clin Oncol 23:4039-4047, 2005.

Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Reaman GH, Adamson PC. A Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children’s Oncology Group Study. J Clin Oncol 23:6172-6180, 2005.

Last update: June 2009

 

Email This Article Email This Article   |   Print Print